Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.
Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors. The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
“The limitations of current checkpoint therapies are evident, as they don’t fully target the diverse spectrum of mechanisms associated with non-responsiveness and treatment resistance,” said Dr. Ali H. Munawar, CEO of Conformation-X Therapeutics.
Despite the pivotal role of PD-1/PD-L1 inhibitors in cancer immunotherapy, several peer-reviewed clinical studies have shown that the overall response rate across various cancers remains at or below 20%. Patients facing resistance to conventional checkpoint therapies encounter a range of challenges. This includes tumors that inherently possess low immunogenicity, are less likely to trigger an immune response, and immune exclusion, which restricts immune cells from the tumor microenvironment (TME). Moreover, complex genetic landscapes featuring oncogenic drivers and epigenetic modifications further contribute to immune evasion and influence treatment outcomes.
Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts.”
The recent capital infusion accelerates the company towards translational studies of its lead asset and facilitates the expansion of its pipeline. The company's pipeline encompasses diverse drug target classes, extending beyond the current landscape of immune checkpoints to include novel soluble and epigenetic checkpoints while continuing to innovate within the B7-family of receptors.
“Achieving selective therapeutic targeting of HHLA2 demonstrates our team’s profound understanding of its intricate structure-function relationship and the critical role that HHLA2 plays in tumor immune evasion. Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.
About Conformation-X Therapeutics
Conformation-X utilizes a proprietary discovery platform enriched by structural insights to pioneer therapeutics with innovative mechanisms of action. The company is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system. The company’s premier preclinical asset includes a potent HHLA2-inhibitor that selectively restores its immune-suppressing effect with application in PD1/PDL1-negative cancers. To learn more visit www.conformationx.com.
Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
About Pledge Therapeutics
Pledge Therapeutics is headquartered in Greater Boston with a second R&D branch in Leuven, Belgium. Pledge harnesses a state-of-the-art platform that merges structure-based drug design with biophysics, facilitating breakthroughs in the design of treatments for challenging therapeutic targets.
Pledge is grounded in a collaborative ethos, drawing on a network of experienced life sciences entrepreneurs, clinicians, and discovery scientists. Under its management umbrella, Pledge unites two independent biotech ventures: Orthogon Therapeutics, which specializes in antiviral treatments, and Conformation-X, dedicated to advancements in immune-oncology. This integrated model reinforces Pledge’s mission to revolutionize patient care across diverse therapeutic areas. More info on www.pledge-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403623298/en/
Contact information
Media
Ali H. Munawar, Ph.D.
amunawar@conformationx.com
1-339-502-8643
Maria Martin
mmartin@pledge-tx.com
1-339-502-8630
Krishna Kandala
kkandala@pledge-tx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program17.10.2025 03:42:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and the US, announced today its selection by the United States Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of its selection, Dompé has been awarded a voucher granting a significantly shortened review timeline for marketing application and enhanced collaboration with the FDA. Dompé intends to apply the voucher for the Biologic License Application (BLA) for an intranasally administered formulation of Nerve Growth Factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION). The intranasal administration of NGF is a novel approach, patented by Dompé, offering a non-invasive delivery method. “The CNPV represents a strategic lever to accelerate access to transformative therapies for patients with unmet medical needs as NAION,” said Sergio Dompé, Executive President at Dompé. “Building on our pioneering ach
Bentley Systems Announces Winners of the 2025 Going Digital Awards17.10.2025 02:00:00 EEST | Press release
(Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the winners of the 2025 Going Digital Awards. The annual awards honor the extraordinary work of infrastructure professionals and their innovative use of Bentley software to improve the way infrastructure is designed, built, and operated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016841527/en/ Bentley Systems announced the winners of the 2025 Going Digital Awards on October 16, 2025 (Photo courtesy of Bentley Systems) This year, nearly 250 projects were nominated by organizations in 47 countries. Winners were selected across 12 categories by a panel of independent judges during Bentley’s Year in Infrastructure conference, held October 15-16 in Amsterdam. “Congratulations to this year’s Going Digital Award winners,” said Chris Bradshaw, chief sustainability and e
Kinaxis Inc. to Host Third Quarter 2025 Financial Results Conference Call on November 6, 202517.10.2025 00:00:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its third quarter ended September 30, 2025. The call will be hosted on Thursday, November 6 at 8:30 a.m. Eastern Time by Bob Courteau, interim chief executive officer and chair, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the third quarter after the close of markets on Wednesday, November 5, 2025. CONFERENCE CALL DETAILS DATE: Thursday, November 6, 2025 TIME: 8:30 a.m. Eastern Time CALL REGISTRATION:https://registrations.events/direct/Q4I91416498WEBCAST:https://events.q4inc.com/attendee/875765587 (available for three months) Advance call registration Participants must register in advance for the live call. After registering, instructions on how to join the call will automatically be emailed, including dial-in informa
HCLTech and Zscaler Expand Partnership for AI-Powered Security and Network Transformation16.10.2025 21:13:00 EEST | Press release
HCLTech, a leading global technology company, and Zscaler™, a leader in cloud security, announced the expansion of their strategic partnership to provide AI-powered network transformation and enhanced zero-trust security services to enterprises worldwide. Under the new partnership scope, Zscaler's Zero Trust Exchange™ platform has been integrated with HCLTech's Cybersecurity Fusion Center (CSFC) platform. HCLTech’s AI capabilities, including SecOps and Responsible AI guardrails within HCLTech AI Force and AI Foundry are key to this partnership. This collaboration aims to enhance enterprise resilience and achieve business outcomes with a cloud-first, scalable security solution. HCLTech's Universal Managed Detection and Response (UMDR) services now integrate with Zscaler Internet Access™ (ZIA™), Zscaler Private Access™ (ZPA™) and other Zscaler components, providing context-rich threat detection, advanced analytics and faster response powered by AI and automation. Other key highlights of
Beyon Cyber and Haven Sign MoU to Launch Advanced AI-Powered SOC Capabilities in the UK and Worldwide16.10.2025 20:58:00 EEST | Press release
Beyon Cyber, part of the Beyon Group and the fastest growing cyber security company in the Middle East, has signed a Memorandum of Understanding (MoU) with Haven Cyber Technologies, a global cyber security services provider and a Microsoft Solutions Partner, through its UK-based subsidiary ITC Secure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016047852/en/ Beyon Cyber and Haven Sign MoU Under the MoU, Beyon Cyber and Haven will form a strategic partnership to revolutionize cyber security operations through the launch of advanced AI-driven Security Operations Centers (AI SOCs) in the United Kingdom and worldwide. As part of this collaboration, Haven will integrate Beyon Cyber’s cutting-edge AI SOC platform, Orryx AI, into its operations; harnessing the power of smart automation and agentic AI workflows to enhance threat detection, investigation, hunting, intelligence, and response. This partnership will enable both or
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom